

Patient Name REPORTVALIDATION,AUTOMATION D...	Patient ID RVDMOHB022	Age 40	Gender F	Order # RVDMOHB022
Ordering Phys		DOB 01/01/1971		
Client Order # RVDMOHB022	Account Information			Report Notes
Collected 09/01/2011 08:40	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 09/02/2011 06:59				

Test	Flag	Results	Unit	Reference Value	Perform Site*
BCR/ABL Mutation, ASPE			REPORTED 09/01/2011 11:31		
Specimen Type		Peripheral blood			MCR
BCRABL Fusion Form		p210			MCR
Final Diagnosis:		Peripheral blood, BCR/ABL Kinase Domain Mutation Analysis:			MCR
<p>Positive. Two mutations were detected in the ABL kinase domain region. The dominant mutation with its corresponding amino acid change is T315I. Additional mutations with corresponding amino acids include: E355G. These mutations have individually been associated with clinically significant resistance to imatinib therapy (O'Hare T, et al. Blood 2007; 110:2242-2249). The significance of finding more than one mutation in a given patient is not clear.</p> <p>Per provided client information, this patient is reported to have a p210 BCR-ABL mRNA transcript type.</p> <p>Signing Pathologist: Carey Lueck This assay detects approximately 80% of the currently described and most frequently occurring ABL kinase domain mutations, which have been associated with significant clinical or in vitro resistance to tyrosine kinase inhibitor therapy (M351T, T315I, E255K, H396R, F359V, M244V, E355G, G250E, F317L, Y253H, Y253F, and Q252H). Additional mutations of potential or unknown significance are not covered by this test methodology and therefore cannot be excluded.</p> <p>Method Summary: Total RNA was extracted and nested reverse transcription PCR was performed to detect the BCR/ABL transcript and ABL kinase domain (KD) region. Kinase domain mutations (KDM) were evaluated using a fluorescent multiplex allele-specific extension (ASPE) assay and analyzed for specific mutations using liquid bead array platform (see Mayo Medical Laboratories Interpretive Handbook for method details). Laboratory developed test.</p>					

* Performing Site:

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First St SW Rochester, MN 55905	Lab Director:
-----	---	---------------

Patient Name REPORTVALIDATION,AUTOMATION D...	Collection Date and Time 09/01/2011 08:40	Report Status Final
Page 1 of 1		** End of Report **

* Report times for Mayo performed tests are CST/CDT